AdventHealth, Moffitt form collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Moffitt Cancer Center and AdventHealth are partnering to provide cancer treatment and better access to cancer prevention, education, cancer screenings and early phase clinical trials for patients in Florida.

The partnership will develop a cancer research agenda shared across both organizations, which will include expanding research activities and recruitment of innovative cancer investigators to the AdventHealth Orlando and Celebration campuses.

The two organizations plan to establish a clinical research facility and chemotherapy/immunotherapy infusion program at AdventHealth Celebration, focused on solid tumor malignancies and malignant hematology, which will allow Central Florida patients to receive critical treatments closer to home.

At AdventHealth Celebration, researchers from both organizations will conduct early phase clinical studies—the first and only phase I site in Central Florida.

This partnership extends to AdventHealth’s West Florida division as well, where a new Moffitt outpatient satellite cancer center is under construction at AdventHealth Wesley Chapel.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login